Navigation Links
Stemline Therapeutics Raises $12.5 Million
Date:4/9/2008

Proceeds to advance oncology therapeutics targeting cancer stem cells

NEW YORK, April 9, 2008 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company and a leading developer of oncology compounds directed to cancer stem cell targets, today announced that it has completed a $12.5 million round of financing with healthcare funds managed by Pequot Capital Management, Inc.

Stemline's CEO, Ivan Bergstein, MD, said. "We are very pleased to have consummated this transaction with a fund of this caliber. The capital provides us with significant runway to advance our clinical program, while continuing to build out our pipeline, discovery platform, and comprehensive IP estate. Moreover, this financing allows us to continue to strengthen our leadership position in the rapidly emerging cancer stem cell field."

About Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. is a clinical stage biotechnology company developing novel oncology compounds directed to cancer stem cell targets. Stemline's lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I human trial. In addition, Stemline is developing a portfolio of compounds directed at this and other high value cancer stem cell targets of a variety of hematological and solid cancers. Stemline has also built a robust discovery platform called "StemScreen(R)" which the Company has utilized to identify multiple compounds that target and impair cancer stem cells. For more information, please visit the Company's website at http://www.stemline.com.


'/>"/>
SOURCE Stemline Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
2. Amsterdam Molecular Therapeutics Part of Next Biotech Index
3. Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium
4. Alba Therapeutics Announces Appointment of Bruce A. Peacock as its Chief Executive Officer
5. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
6. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
7. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
8. Mercury Therapeutics Patents Filed
9. Cell Therapeutics, Inc. Announces Filing of Form 10-K
10. Vicus Therapeutics Announces Participation at 15th International Molecular Medicine Tri-Conference
11. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... OF PRUSSIA, PA (PRWEB) , ... December 01, 2016 , ... ... research is through industry-wide collaboration, standardization and a beautiful technology experience. All three tenets ... convened more than 100 clinical trial leaders from over 40 sponsor, CRO and site ...
(Date:12/2/2016)... ... December 02, 2016 , ... Robots will storm the ... on December 3rd, 2016. The event, which is held on the United Nations International ... Americans with Disabilities back into the workplace. Suitable Technologies is partnering with NTI to ...
(Date:12/2/2016)... , Dec. 2, 2016 /PRNewswire/ - bioLytical Laboratories, a world leader in rapid infectious ... Kenya,s Pharmaceutical Association members. (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ... ... , , ... the Kenya Pharmaceutical Association (KPA) to introduce the INSTI HIV Self Test to 350 ...
(Date:11/30/2016)... November 30, 2016 The global ... players hold a dominant share in the overall market. ... International, Inc., and Merck KGaA, held a lion,s share ... Market Research observes that these companies are expected to ... products that are do not require rabbit pyrogen testing ...
Breaking Biology Technology:
(Date:6/22/2016)... On Monday, the Department of Homeland Security ... solutions for the Biometric Exit Program. The Request for ... (CBP), explains that CBP intends to add biometrics to ... United States , in order to deter visa ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
Breaking Biology News(10 mins):